Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

The objective of this study is to apply AclarusDx™ signature in a reference US Center in 160
patients newly referred to one of the three study centers within the Cleveland Clinic,
Center for Brain Health network, for diagnostic workup. Only AclarusDx™ will be added to the
panel of tests usually performed at the centers to establish diagnosis. AclarusDx™ will be
used for investigational use only, not for diagnostic purpose. The ultimate goal is to
define the clinical utility of AclarusDx™ to provide Primary Care Physicians (PCPs) with a
tool that will help them in making the diagnosis of Alzheimer's Disease (AD).

The primary objectives are :

1. To obtain an estimate of the capability of AclarusDx™ to identify AD patients among a
US-based population of newly referred patients suffering from objective memory
impairment which maybe potentially related to multiple and different etiologies.

2. To compare the performance of AclarusDx™ in a US-based population of newly referred
patients with memory impairment with the performance of AclarusDx™ observed in one
comparable European population.